The lawsuit claims that the three drugmakers participated in pay-for-delay deals to prevent the release of a generic, cheaper version of the wakefulness drug Provigil.
The settlement resolves a class-action lawsuit brought by health plans and other indirect purchasers of Provigil.
Read the full report here.
More articles on pharmacy:
10 hospitals seeking pharmacy leadership
Patent protection clause is latest stumbling block for revised NAFTA
Dr. Reddy’s legal win expected to lower cost of opioid addiction treatment
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.